{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:34:14Z","timestamp":1771983254724,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.urolonc.2013.02.010","type":"journal-article","created":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T09:30:55Z","timestamp":1367141455000},"page":"35.e21-35.e30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Interferon alfa in the treatment paradigm for non\u2013muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"Donald","family":"Lamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2013.02.010_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2013.02.010_bib2","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib4","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Bladder cancer. Version 2.2012. Available at: \u3008http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf\u3009; [accessed 19.12.12]."},{"key":"10.1016\/j.urolonc.2013.02.010_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.1988.6.3.476","article-title":"Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study","volume":"6","author":"Torti","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","article-title":"A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1464-410X.2002.02734.x","article-title":"A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder","volume":"89","author":"Malmstr\u00f6m","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2013.02.010_bib8","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eursup.2008.07.009","article-title":"Clinical practice recommendations for the management of non\u2013muscle invasive bladder cancer","volume":"7","author":"Lamm","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urolonc.2013.02.010_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1464-410X.1998.00890.x","article-title":"Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma","volume":"82","author":"Giannakopoulos","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0090-4295(96)00455-4","article-title":"Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder","volume":"49","author":"Portillo","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.02.010_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1994.12.1.7","article-title":"Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study","volume":"12","author":"Boccardo","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0022-5347(05)64556-9","article-title":"Perioperative single dose instillation of epirubicin or interferon-\u03b1 after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study\u2013FinnBladder III long-term results","volume":"168","author":"Rajala","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-4295(97)00303-8","article-title":"Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Gu\u00e9rin and interferon-alpha","volume":"50","author":"Jimenez-Cruz","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.02.010_bib15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.eururo.2010.01.004","article-title":"New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carcinoma","volume":"57","author":"Babjuk","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib18","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2013.02.010_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non\u2014muscle-invasive bladder cancer","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2013.02.010_bib20","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1016\/j.juro.2012.02.1523","article-title":"Bacillus Calmette-Guerin: one third dose versus full dose and one year versus three years of maintenance. Final results of EORTC GU Cancers Group randomized trial 30962 in non muscle invasive bladder cancer. Abstract 1665","volume":"187","author":"Brausi","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib21","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.02.010_bib23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","article-title":"Long-term results of intravesical bacillus Calmette-Gu\u00e9rin therapy for stage T1 superficial bladder cancer","volume":"55","author":"Brake","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.02.010_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)49690-X","article-title":"Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer","volume":"132","author":"Morales","year":"1984","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib26","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.urolonc.2007.10.016","article-title":"Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder\u2014our experience","volume":"26","author":"Mohanty","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib29","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Gu\u00e9in\u2013refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib30","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non\u2014muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.02.010_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo\u00ae working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"issue":"Suppl. 1","key":"10.1016\/j.urolonc.2013.02.010_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1100\/tsw.2004.81","article-title":"Superficial bladder cancer therapy","volume":"4","author":"Schenkman","year":"2004","journal-title":"Sci World J"},{"key":"10.1016\/j.urolonc.2013.02.010_bib36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14737140.3.6.809","article-title":"Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer","volume":"3","author":"O'Donnell","year":"2003","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2013.02.010_bib37","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","article-title":"Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression","volume":"14","author":"Kaempfer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","article-title":"Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value","volume":"155","author":"de Reijke","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0090-4295(98)00188-5","article-title":"Intravesical bacille Calmette-Gu\u00e9rin induces the antiangiogenic chemokine interferon-inducible protein 10","volume":"52","author":"Poppas","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.02.010_bib40","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Gu\u00e9rin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2013.02.010_bib41","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-\u03b1 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib42","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/bjc.1997.315","article-title":"Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder","volume":"75","author":"Molt\u00f3","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2013.02.010_bib43","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","article-title":"Role of IL-12 in the induction and potentiation of IFN-\u03b3 in response to bacillus Calmette-Gu\u00e9rin","volume":"163","author":"O'Donnell","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib44","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-5347(01)61832-9","article-title":"Effects of bacillus Calmette-Gu\u00e8rin and interferon alpha-2B on cytokine production in human bladder cancer cell lines","volume":"161","author":"Zhang","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib45","first-page":"2726","article-title":"Interferon-\u03b1-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule","volume":"5","author":"Slaton","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2013.02.010_bib46","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4161\/cbt.6.6.4088","article-title":"Interferon-\u03b1 induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells","volume":"6","author":"Papageorgiou","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.urolonc.2013.02.010_bib47","first-page":"31","article-title":"Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study","volume":"17","author":"Natsis","year":"1997","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.urolonc.2013.02.010_bib48","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/08923970903300151","article-title":"Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy","volume":"32","author":"Agarwal","year":"2010","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib49","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/S0022-5347(01)68241-7","article-title":"Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B","volume":"158","author":"Downs","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib50","first-page":"335","article-title":"Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications","volume":"310","author":"Lamm","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.urolonc.2013.02.010_bib51","doi-asserted-by":"crossref","unstructured":"Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL. Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010;184:1915\u201319.","DOI":"10.1016\/j.juro.2010.06.147"},{"key":"10.1016\/j.urolonc.2013.02.010_bib52","unstructured":"Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol 2003;10:1790\u201315."},{"key":"10.1016\/j.urolonc.2013.02.010_bib53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","article-title":"Bacillus Calmete-Gu\u00e9rin plus interferon-\u03b12B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity","volume":"21","author":"Lam","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib54","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-\u03b1 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib55","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib56","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Gu\u00e9rin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.02.010_bib58","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","article-title":"National BCG\/Interferon Investigator Group. Factors affecting response to bacillus Calmette-Gu\u00e9rin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.02.010_bib59","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.urology.2011.04.070","article-title":"Diminished efficacy of bacille Calmette-Gu\u00e9rin among elderly patients with nonmuscle invasive bladder cancer","volume":"78","author":"Margel","year":"2011","journal-title":"Urology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:07:04Z","timestamp":1761041224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143913000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1078143913000732"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.02.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon alfa in the treatment paradigm for non\u2013muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}